PF-04634817

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NamePF-04634817
Drug Alias NamePF-4634817PF-04634817PF-46334817
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-C chemokine receptor type 2 antagonistsC-C chemokine receptor type 5 antagonists
TargetsC-C chemokine receptor type 5C-C chemokine receptor type 2
Therapy Area/IndicationsDiabetic macular oedemaRenal InsufficiencyDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[19] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedemaRenal InsufficiencyDiabetic Nephropathies

Other Information

ATC CodeN/A
Related LinksN/A